BACKGROUND Retinopathy of prematurity (ROP) is a blinding morbidity of preterm infants. Our current screening criteria have remained unchanged since their inception and lack the ability to identify those at greatest risk. OBJECTIVES We sought to comprehensively analyze numerous proposed maternal, infant, and environmental ROP risk variables in a robustly phenotyped population using logistic r...

Objective. Current American retinopathy of prematurity (ROP) screening guidelines is imprecise for infants ≥ 30 weeks with birth weights between 1500 and 2000 g. Our objective was to evaluate a risk factor based approach for screening premature infants at low risk for severe ROP. Study Design. We performed a 13-year review from Intermountain Health Care (IHC) data. All neonates born at ≤32 week...

BACKGROUND To understand the characteristics, ophthalmic outcomes, and risk factors of retinopathy of prematurity (ROP) in patients with birth weight (BW) greater than 1500 g. The applicability of the ROP screening criteria to the Taiwanese population was also examined. METHODS The study included 104 eyes from 54 ROP patients who had BW greater than 1500 g from 1981 to 2008. Demographic infor...

PURPOSE To describe a novel retinopathy of prematurity (ROP) screening model incorporating birth weight, gestational age, and postnatal weight gain that maintains sensitivity but improves specificity in detecting all grades of ROP compared to current 2013 screening guidelines. METHODS The medical records of 499 neonates from a single tertiary referral center who met the 2013 screening guideli...

purpose: to determine the incidence of retinopathy of prematurity (rop) and to evaluate the possible neonatal risk factors for rop. methods: this cross-sectional study included all premature infants born at hospitals affiliated to tehran medical university, tehran-iran who were referred within 4-6 weeks after delivery to farabi eye hospital from 2004 to 2005. inclusion criteria were birth weigh...

PURPOSE To compare the efficacy of intravitreal injection of ranibizumab (IVR) monotherapy and laser therapy for treatment-requiring retinopathy of prematurity (ROP) in Zone II. METHODS A prospective, randomized, controlled single-center trial was applied from January 2014 to December 2014; infants who were diagnosed as Zone II treatment-requiring ROP (i.e., Zone II Stage 2 or 3 ROP with plus...